Imaging cell death: Neves and Brindle focus on apoptosis imaging probes that have shown promise in preclinical and clinical settings and provide an overview of challenges associated with cell death detection.
New age in radiolabeled agent therapy? Divgi offers perspective on the challenges and potential of radiopharmaceutical therapy development, with a focus on those agents intended for use with companion diagnostic imaging biomarkers.
64Cu-based hypoxia imaging: Dearling and Packard provide context and background for an article in this issue of JNM on biodistribution of 64Cu-ATSM, a potential hypoxia tracer, and its precursor 64Cu-acetate.
131I-BA52 benzamide for melanoma therapy: Mier and colleagues report on experience with labeling procedures for radioiodination of benzamides and on initial dosimetry data and therapeutic application of 131I-BA52, a novel melanin-binding benzamide, in patients with metastatic melanoma.
Melanoma staging and123I-BZA2: Cachin and colleagues describe the development of a radiolabeled benzamide derivative that binds to melanin pigment in melanoma cells and compare its efficacy in scintigraphy with that of 18F-FDG PET/CT in a phase III clinical study.
64Cu-trastuzumab PET in breast cancer: Mortimer and colleagues evaluate 64Cu-DOTA-trastuzumab PET/CT for detection and measurement of tracer uptake in patients with human epidermal growth factor receptor 2–positive breast cancer.
18F-FDOPA PET in irradiated brain metastases: Lizarraga and colleagues examine the diagnostic accuracy as well as the prognostic power of 18F-FDOPA PET for differentiating recurrent or progressive brain metastases from late or delayed radiation injury.
Effects of small tumor volumes: Brooks and Grigsby look at the effect of inclusion of very small tumor volumes on intratumoral uptake heterogeneity metrics derived from data from the current generation of whole-body 18F-FDG PET scanners.
Cancer targeting with vitamin B12: Sah and colleagues investigate tumor-specific uptake of 99mTc-PAMA-cobalamin, a vitamin B12 derivative recognized by haptocorrin, in 10 patients with various metastatic tumors.
Cardiac CTA and SPECT MPI fusion: Kiri˛li and colleagues explore the additional diagnostic value of a software-based CT angiography/SPECT myocardial perfusion imaging fusion system over conventional side-by-side analysis in patients with suspected coronary artery disease.
Interpretation standards for 82Rb-ARMI: Renaud and colleagues detail standardized imaging protocols developed for a multicenter trial to evaluate accuracy, outcomes, and cost effectiveness of low-dose 82Rb perfusion imaging using 3-dimensional PET/CT technology.
11C-MK-8278 for brain receptor occupancy: Laere and colleagues evaluate biodistribution, dosimetry, and quantification of 11C-MK-8278, a highly brain-penetrant and selective agent, in humans and assess its utility with PET in occupancy studies of 2 novel histamine H3 inverse agonists.
18F-DTBZ PET in early Parkinson disease: Lin and colleagues determine the capability of 18F-DTBZ, a novel radiotracer targeting vesicular monoamine transporter type 2, for PET detection of monoaminergic degeneration in early Parkinson disease.
Costs of a CAD management strategy: Delgado and colleagues present a preliminary cost analysis of a combination intervention using PET and comprehensive lifestyle modification to reverse atherosclerosis.
Agreement in PET/MR and PET/CT: Al-Nabhani and colleagues prospectively compare whole-body PET/MR and PET/CT imaging, qualitatively and quantitatively, in oncologic patients and assess the confidence and degree of inter- and intraobserver agreement in anatomic lesion localization.
18F-FDG clinical Cerenkov imaging: Thorek and colleagues report on the feasibility of Cerenkov luminescence imaging in patients undergoing diagnostic 18F-FDG scans for detection of nodal disease.
Imaging cardiac sarcoidosis: Schatka and Bengel provide an educational overview of the clinical background and current state of diagnostic modalities and treatment for cardiac sarcoidosis.
225Ac-labeled antivascular liposomes: Bandekar and colleagues describe the use of targeted liposomes loaded with the α-particle generator 225Ac to selectively kill prostate-specific membrane antigen–expressing cells and discuss the potential for targeted antivascular radiotherapy.
Atherosclerosis imaging with liposomes: Ogawa and colleagues detail the preparation of radiolabeled phosphatidylserine liposomes for macrophage targeting in SPECT detection of vulnerable plaques.
Enhancing tumor uptake of radiopeptides: Nock and colleagues explore the hypothesis that in vivo coadministration of specific enzyme inhibitors could improve peptide bioavailability and tumor uptake in tumor xenografts in mice.
Copper metabolism in hypoxia targeting: Hueting and colleagues compare 64Cu retention after administration of 64Cu-ATSM or 64Cu-acetate in vitro in CaNT and EMT6 cells and in mice bearing corresponding tumors.
90Y glass microsphere efficacy: Walrand and colleagues explore dose distribution questions posed by hepatic toxicities associated with 90Y resin and glass microsphere liver radioembolization.
11C-CUMI-101 and 5-HT1AR receptors: Shrestha and colleagues examine the functional properties and selectivity of this ligand, both in vitro and in a primate model, and discuss the implications of their findings for PET applications in humans.
18F-FTC-146 in rats and squirrel monkeys: James and colleagues assess this σ-1 receptor radiotracer in rats, squirrel monkeys, and human serum/liver microsome studies to provide supporting data for eventual translation to clinical PET imaging.
Dual-tracer dynamic PET: Guo and colleagues investigate the utility of dual-tracer dynamic PET imaging with 18F-alfatide II and 18F-FDG for parametric monitoring of tumor angiogenesis and metabolism in response to therapy.
PET/MR with continuous table motion: Braun and colleagues describe the technical implementation of simultaneous PET and MR data acquisition with continuous table motion.
Uniformity assessment with noise texture analysis: Nelson and colleagues develop, test, and validate a new uniformity analysis metric capable of accurately identifying structures and patterns present in nuclear medicine flood-field uniformity images.
- © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.